Effect of antiretroviral therapy on progression of endothelial dysfunction in acquired immune deficiency syndrome patients


  • Zorinsangi Varte Department of General Medicine, Zoram Medical College, (MIMER), Falkawn, Aizawl, Mizoram, India
  • Naveen P. Department of Physiology, Zoram Medical College, (MIMER), Falkawn, Aizawl, Mizoram, India
  • Wendy L. Ralte Department of Radio-Diagnosis, Zoram Medical College, (MIMER), Falkawn, Aizawl, Mizoram, India




AIDS, Antiretroviral therapy, Endothelial dysfunction


Background: Though the natural history of Human Immunodeficiency Virus (HIV) infection in many patients has been dramatically altered through the use of antiretroviral therapy, this treatment paradigm of chronic chemotherapy may not be sustainable given the short and long-term toxicities of these medications. Currently, there is lack of data in the Indian literature regarding study of endothelial dysfunction in HIV patients. The purpose of our research was to study the effect of anti-retroviral therapy on the progression of endothelial dysfunction in HIV/AIDS patients.

Methods: The study comprises a total number of 30 adult HIV positive patients of both sex with confirmed HIV seropositivity and CD 4+T cell count < 200/µl. None of these patients had ever received anti retroviral therapy (ART). These patients were subjected to detailed clinical examination and markers of endothelial dysfunction - Flow mediated vasodilatation (FMD) of brachial artery, S. Nitrite and C-reactive protein (CRP) were performed before starting ART. Study group patients were started on ART, they received triple drug ART (Lamivudine 150 mg BD, Stavudine 30 mg BD, Nevirapine 200 mg BD). In patients on ART after a period of 6 months, markers of endothelial dysfunction - FMD, S. Nitrite and CRP tests were reassessed.

Results: FMD (4.08±3.58) and S. Nitrite (20.83±13.75) were also depressed after six months of anti retroviral therapy. Also, patients showed more CRP positivity and higher titres after ART. CD 4+T cell count before ART (124.16±84.46) and after ART (186.63±70.96). This rise in count was statistically significant.

Conclusions: HIV patients who are receiving ART demonstrate a number of metabolic abnormalities with more severe depression in markers of endothelial function.


UNAIDS AIDS Epidemic Update, July 2018. Available at: https://www.unaids.org/en/20180718_GR2018.

Grunfeld C, Pang MI, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metabol. 1992;74(5):1045-52.

Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-60.

Bussolino F, Mitola S, Serini G, Barillari G, Ensoli B. Interactions between endothelial cells and HIV-1. Int J Biochem Cell Biol. 2001;33:371-90.

CDC Update AIDS. MMWR 18 December 1992;41(RR-17):1-19. Available at: https://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm.

Varte Z, Naveen P, Ralte WL. Prevalence of endothelial dysfunction in acquired immune deficiency syndrome patients and its correlation with degree of immunodeficiency. Int J Adv Med. 2019;6(3): 668-72.

Polo R, Verdejo J, Gomez M. Lipodystrophy related to NRTI inhibitors in HAART therapy. 3rd Conference on nutrition and HIV infection. Cannes 1999.

Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354(9184):1112-5.

Chêne G, Angelini E, Cotte L, Lang JM, Morlat P, Rancinan C, et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis. 2002;34(5):649-57.

Thiebaut R, Dabis F, Malvy D, Jacqmin-Gadda H, Mercie P. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. Groupe d'Epidémiologie Clinique du Sida en Aquitaine (GECSA). J Acquired Immune Deficiency Syndromes (1999). 2000 Mar;23(3):261-5.

Bonnet D, Aggoun Y, Szezepanski I, Bellal N, Blanche S. Arterial stiffness and endothelial dysfunction in HIV-infected children. AIDS. 2004;18(7):1037-41.

Sármán B, Tóth M, Somogyi A. Role of endothelin‐1 in diabetes mellitus. Diabetes/Metabolism Reviews. 1998;14(2):171-5.

Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ, Visscher B, et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med. 2006;166(1):64-70.

Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32(1):130-9.




How to Cite

Varte, Z., P., N., & Ralte, W. L. (2019). Effect of antiretroviral therapy on progression of endothelial dysfunction in acquired immune deficiency syndrome patients. International Journal of Research in Medical Sciences, 7(6), 2111–2115. https://doi.org/10.18203/2320-6012.ijrms20192482



Original Research Articles